Tan Sing-Huang, Wolff Antonio C
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-189, Baltimore, MD 21231, USA.
Curr Oncol Rep. 2008 Jan;10(1):27-37. doi: 10.1007/s11912-008-0006-y.
Increasing interest has emerged in the role of ovarian function suppression, which has shown equivalence to adjuvant CMF (cyclophosphamide, methotrexate, 5-fluorouracil), whether achieved by surgery or irradiation, in breast cancer patients. Studies have suggested temporary amenorrhea can confer benefit in early breast cancer, giving luteinizing hormone-releasing hormone (LH-RH) agonists an advantage over oophorectomy or radiation. Compared with no therapy, LH-RH agonists reduce risks of recurrence and death among women younger than 50 years of age who have hormone receptor-positive tumors. Trials are assessing the benefits of adding LH-RH agonists to aromatase inhibitors, tamoxifen, or after chemotherapy in women remaining premenopausal, and the necessity for adjuvant chemotherapy with combined ovarian ablation and antiestrogen therapy.
卵巢功能抑制的作用已引起越来越多的关注，在乳腺癌患者中，无论是通过手术还是放疗实现的卵巢功能抑制，都已显示出与辅助性CMF（环磷酰胺、甲氨蝶呤、5-氟尿嘧啶）等效。研究表明，暂时性闭经对早期乳腺癌有益，这使促黄体生成素释放激素（LH-RH）激动剂比卵巢切除术或放疗更具优势。与不进行治疗相比，LH-RH激动剂可降低激素受体阳性肿瘤的50岁以下女性的复发风险和死亡风险。试验正在评估在绝经前女性中，将LH-RH激动剂添加到芳香化酶抑制剂、他莫昔芬中或化疗后带来的益处，以及联合卵巢去势和抗雌激素治疗进行辅助化疗的必要性。
